The interventional effect of astragaloside IV on rodent models of myocardial fibrosis: A systematic review and meta-analysis

Haozhe Li¹Yunhang Chu²Yue Wang^1,3*Yuan Wang¹Yebo Zhang¹

• ¹Inner Mongolia Medical University, Inner Mongolia Hohhot, China
• ²Changchun University of Chinese Medicine, Jilin Province Changchun, China
• ³Inner Mongolia Autonomous Region People's Hospital, Inner Mongolia Hohhot, China

Objective:To evaluate the interventional effects of astragaloside in a rodent mo del of myocardial fibrosis(MF), this study was conducted. Methods:Data from studies related to the intervention of astragaloside IV (AS-I V) in rodent models with MF were systematically retrieved and extracted. The outcome indices included Collagen Volume Fraction (CVF), Left Ventricular E nd-Systolic Diameter (LVESD), Left Ventricular End-Diastolic Diameter (LVED D), Interventricular Septal Thickness at Diastole (IVSd), Left Ventricular Posteri or Wall Diastolic Thickness (LVPWd), Left Ventricular Internal Diameter at Di astolic (LVIDd), Left Ventricular Mass Index (LVMI), Left Ventricular Fraction al Shortening (LVFS), Left Ventricular End-Diastolic Pressure (LVEDP), Left Ventricular Systolic Pressure (LVSP), Left Ventricular Internal Diameter at Syst ole (LVIDs), Left Ventricular Ejection Fraction (LVEF), Maximum Rate of Sys tolic Pressure Rise (+dp/dtmax), Maximum Rate of Diastolic Pressure Fall (-dp/ dtmax), and other hemodynamic indices. Additionally, it included Lactate Dehy drogenase (LDH), Tumor Necrosis Factor-Alpha (TNF-α), Body Weight (BW), and Heart Rate (HR). The methodological quality of the studies was assessed using the SYRCLE risk of bias tool, and these results were statistically analyz ed by meta-analysis.Additionally, meta-regression and subgroup analyses were p erformed according to species, administration dosage, and administration duratio n, aiming to further deepen the understanding of the study results and provide references for relevant clinical research. Results:A total of 38 studies were incorporated into the Meta-analysis. The fin dings indicated that AS-IV led to a reduction in morphostructural indices, inclu ding CVF, LVESD,LVEDD, IVSd, LVPWd, LVMI. Moreover, it decreased LVE DP and LVSP, while increasing hemodynamic indices such as LVEF, LVFS, +d p/dtmax, and-dp/dtmax.Additionally, astragaloside decreased biochemical and phy siological indices like LDH, TNF-α, and HR, and BW. Nevertheless, it exerted no significant impact on the levels of LVIDs and LVIDd in the model. Conclusion: AS-IV can be used as a supportive treatment for MF, acting throu gh a variety of mechanisms such as relieving inflammation, relieving myocardi al injury and oxidative stress, thereby contributing to the improvement of ventr icular diastolic and contractile capacity and reducing necrosis and apoptosis ofc ardiomyocytes.